Creative Biolabs has expanded its specialized antibody portfolio targeting structural and envelope proteins from HIV-1, HIV-2, and HTLV-1.



SHIRLEY, NY, September 24, 2026 /24-7PressRelease/ -- Human retroviruses remain an important area of research across virology, immunology, vaccine development, and diagnostic assay development. Creative Biolabs has expanded its specialized antibody portfolio targeting structural and envelope proteins from HIV-1, HIV-2, and HTLV-1.

Research antibodies targeting defined viral proteins can support studies of viral entry, epitope recognition, immune responses, and diagnostic assay development. Creative Biolabs' retrovirus-focused antibody portfolio is designed for research applications involving HIV-1, HIV-2, and HTLV-1 proteins.

At the forefront of the fight against the most prevalent strain of the human immunodeficiency virus is the study of the viral envelope. The gp140 protein, an uncleaved ectodomain of the HIV-1 envelope glycoprotein, is a primary target for broadly neutralizing antibodies and vaccine design. Creative Biolabs offers an anti-gp140 HIV-1 antibody for research applications involving HIV-1 envelope biology, antigen recognition, and related assay development.

While HIV-1 accounts for the majority of global infections, HIV-2 presents unique clinical challenges due to its distinct genetic makeup and different disease progression rates. Because gp36 is an HIV-2 envelope-associated antigen, antibodies targeting gp36 can be useful research tools for studying antigen recognition, cross-reactivity, and the development and evaluation of HIV-2-focused assay concepts.

Beyond HIV, the human T-cell lymphotropic virus type 1 (HTLV-1) represents another significant retroviral threat, being the causative agent of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy. HTLV-1 gag p19 is a viral core protein commonly investigated in studies of HTLV-1 biology, viral protein expression, and immune recognition. Creative Biolabs' anti-HTLV-1 gag p19 antibody is intended for research applications such as Western blot, ELISA, and immunohistochemistry, supporting research into HTLV-1 pathogenesis and related virology questions.

"Retrovirus research often depends on reagents that distinguish specific viral proteins and support different experimental formats," said a senior scientist at Creative Biolabs. "By expanding antibody coverage across HIV-1, HIV-2, and HTLV-1 targets, we aim to give researchers additional options for studying viral proteins, antigen recognition, and assay development."

Creative Biolabs provides retrovirus-targeted antibodies and custom antibody development services for research applications in virology and infectious disease. For more information about the complete range of retrovirus-targeted antibodies and custom services, please visit https://www.antibody-creativebiolabs.com/.

For research use only. Not for use in diagnostic or therapeutic procedures.

About Creative Biolabs
Creative Biolabs is a specialized custom services provider with extensive experience in antibody development and engineering. Committed to advancing medical science, the company offers a comprehensive portfolio of high-quality reagents and innovative assay platforms, supporting clients globally in the fields of infectious disease research and virology.

Read the original story here: https://www.24-7pressrelease.com/press-release/538954/creative-biolabs-expands-antibody-portfolio-for-hiv-and-htlv-research

Press Release Service and Press Release Distribution by 24-7 Press Release Newswire